|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments (Note 5) | ||||||||||||||||||||
| Accounts receivable, net of allowances of $16.0 and $15.0, respectively | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Inventories (Note 2) | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Current assets of discontinued operations (Note 5) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term investments (Note 5) | ||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other assets (Note 2) | ||||||||||||||||||||
| Non-current assets of discontinued operations (Note 5) | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued and other liabilities (Note 2) | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Current liabilities of discontinued operations (Note 5) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Contingent consideration liabilities (Note 13) | ||||||||||||||||||||
| Taxes payable (Note 19) | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Uncertain tax positions | ||||||||||||||||||||
| Litigation settlement accrual | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Non-current liabilities of discontinued operations (Note 4) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | ||||||||||||||||||||
| Common stock, $1.00 par value, 1,050.0 shares authorized, 661.7 and 658.7 shares issued, and 576.6 and 580.7 shares outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss (Note 13) | ||||||||||||||||||||
| Treasury stock, at cost, 85.1 and 78.0 shares, respectively | ||||||||||||||||||||
| Total Edwards Lifesciences Corporation stockholders' equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
